Loading news...
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Azenta (NASDAQ: AZTA - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Risk and Volatility Privia Health Group has a
10x Genomics (NASDAQ: TXG - Get Free Report) and Azenta (NASDAQ: AZTA - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations. Profitability This table compares 10x Genomics and Azenta's net
BURLINGTON, Mass., Jan. 21, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal first quarter 2026 earnings which ended on December 31, 2025, on Wednesday, February 4, 2026, before the market opens.
Azenta, Inc. (NASDAQ: AZTA - Get Free Report) has been assigned an average recommendation of "Hold" from the nine ratings firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the
AZTA, BCBP and CLCO have been added to the Zacks Rank #5 (Strong Sell) List on January 8th, 2026.
ASBFY, AZTA and ALG have been added to the Zacks Rank #5 (Strong Sell) List on December 30, 2025.
BURLINGTON, Mass. , Dec. 29, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to THELEMA S.
Azenta (NASDAQ: AZTA - Get Free Report) and Nyxoah (NASDAQ: NYXH - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation. Volatility and Risk Azenta has a beta of 1.29,
ALG, AZTA and CMG have been added to the Zacks Rank #5 (Strong Sell) List on Dec. 15, 2025.
Azenta, Inc. (AZTA) Analyst/Investor Day Transcript
BURLINGTON, Mass. , Dec. 10, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its Board of Directors has approved a share repurchase program under which the company may repurchase up to $250 million of its outstanding common stock.
Federated Hermes Inc. lessened its stake in shares of Azenta, Inc. (NASDAQ: AZTA) by 9.1% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 700,591 shares of the company's stock after selling 70,500 shares during the period. Federated Hermes Inc. owned about 1.53% of Azenta
BRBR, AZTA and BRDCY have been added to the Zacks Rank #5 (Strong Sell) List on December 9, 2025.
Dallas-based Meros Investment Management purchased 159,945 shares of Azenta valued at $4.6 million in the third quarter. The position represents 2% of Meros's 13F reportable assets under management.
Azenta (NASDAQ: AZTA - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation. Volatility and Risk Azenta has a beta of
Fisher Asset Management LLC lessened its stake in shares of Azenta, Inc. (NASDAQ: AZTA) by 11.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 634,697 shares of the company's stock after selling 81,724 shares during the quarter. Fisher
Veeva Systems (NYSE: VEEV - Get Free Report) and Azenta (NASDAQ: AZTA - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Volatility and Risk Veeva Systems has a beta of
Azenta, Inc. ( AZTA ) Q4 2025 Earnings Call November 21, 2025 8:30 AM EST Company Participants Yvonne Perron - Vice President of Financial Planning & Analysis and Investor Relations John P. Marotta - President, CEO & Director Lawrence Lin - Executive VP & CFO Conference Call Participants David Saxon - Needham & Company, LLC, Research Division Steven Etoch - Stephens Inc., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Jacqueline Kisa - TD Cowen, Research Division Paul Knight - KeyBanc Capital Markets Inc., Research Division Presentation Operator Greetings, and welcome to the Azenta Q4 2025 Financial Results.
Stock News AI and crypto rout rocks markets: Tech-led indexes reversed sharply as investors fretted over lofty AI valuations and tumbling Bitcoin (BTC-USD), whi
Q4'25 reported revenue growth of 6% year over year and 4% on an organic basis FY'25 reported revenue growth of 4% and 3% on an organic basis FY'25 Adjusted EBITDA margin expansion of 310 basis points versus last year FY'26 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points BURLINGTON, Mass. , Nov. 21, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2025.